Search Results - "Yu, ChungPing"
-
1
Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg (GAERS) model of genetic generalized epilepsy with absence seizures
Published in Epilepsia open (01-10-2024)“…Objective We evaluated huperzine A treatment in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model of genetic generalized epilepsy (GGE) with…”
Get full text
Journal Article -
2
A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection
Published in Rapid communications in mass spectrometry (01-01-2007)“…An approach to estimating the levels of drug‐related metabolites in human plasma in the absence of synthesized chemical standards has been developed…”
Get full text
Journal Article -
3
Metabolism and in vitro drug-drug interaction assessment of viloxazine
Published in Xenobiotica (01-11-2020)“…Viloxazine is currently being developed as a treatment for attention deficit/hyperactivity disorder (ADHD). The aim of these studies is to update the…”
Get full text
Journal Article -
4
Metabolism and in vitro drug-drug interaction assessment of viloxazine
Published in Xenobiotica (12-05-2020)“…Viloxazine is currently being developed as a treatment for attention deficit/hyperactivity disorder (ADHD). The aim of these studies is to update the…”
Get full text
Journal Article -
5
Viloxazine Increases Cortical Serotonin Without Inhibiting Serotonin Reuptake at Doses Used to Treat ADHD
Published in CNS spectrums (01-04-2023)“…Abstract Background Most FDA-approved ADHD treatments increase norepinephrine (NE) and dopamine (DA); however, our prior preclinical studies of the…”
Get full text
Journal Article -
6
Characterization of Viloxazine Effects on Cortical Serotonin Neurotransmission at Doses Relevant for ADHD Treatment
Published in CNS spectrums (01-04-2023)“…Abstract Introduction Most ADHD treatments are thought to be effective due to augmentation of dopamine (DA) and norepinephrine (NE). Our prior preclinical…”
Get full text
Journal Article -
7
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Published in CNS drugs (01-06-2021)“…Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment…”
Get full text
Journal Article -
8
P147 - Structural elucidation of the major human metabolites of viloxazine
Published in Drug metabolism and pharmacokinetics (2020)Get full text
Journal Article -
9
New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Published in Journal of experimental pharmacology (2020)“…Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention…”
Get full text
Journal Article -
10
Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder
Published in Journal of experimental pharmacology (2024)“…Viloxazine ER (viloxazine extended-release capsules; Qelbree ), a nonstimulant attention-deficit/hyperactivity disorder (ADHD) treatment, has known activity as…”
Get full text
Journal Article -
11
In vitro pharmacological characterization of SPN-810M (molindone)
Published in Journal of experimental pharmacology (2018)“…Impulsive aggression (IA) is considered a maladaptive form of aggression that is reactive and overt and occurs outside of the acceptable social context. Many…”
Get full text
Journal Article -
12
A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression
Published in Postgraduate medicine (17-02-2019)“…Proper drug categorization enables clinicians to readily identify the agents most appropriate for patients in need. Currently, patients with maladaptive…”
Get full text
Journal Article -
13
Response to comments on “Reproductive toxicology studies supporting the safety of molindone, a dopamine receptor antagonist”
Published in Birth defects research (01-03-2019)Get full text
Journal Article -
14
Reproductive toxicology studies supporting the safety of molindone, a dopamine receptor antagonist
Published in Birth defects research (02-10-2018)“…Background An extended‐release molindone (a dopamine D2 and serotonin antagonist) is currently being developed as a novel treatment for impulsive aggression…”
Get full text
Journal Article